Jounce Therapeutics (Jounce Therapeutics) GF Value Rank : 1 (As of May. 11, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Jounce Therapeutics GF Value Rank?

Jounce Therapeutics has the GF Value Rank of 1.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Jounce Therapeutics's GF Value Rank

For the Biotechnology subindustry, Jounce Therapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jounce Therapeutics's GF Value Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jounce Therapeutics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Jounce Therapeutics's GF Value Rank falls into.

Jounce Therapeutics GF Value Rank Related Terms

Thank you for viewing the detailed overview of Jounce Therapeutics's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Jounce Therapeutics (Jounce Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jounce Therapeutics Inc (NAS:JNCE) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

780 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.jouncetx.com

Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company primarily operates only in the United States. The company has developed a suite of integrated technologies that comprise a Translational Science Platform, enabling it to comprehensively interrogate the cellular and molecular composition of tumors.

Executives

Concentra Merger Sub, Inc.	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Concentra Biosciences, Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Richard /ca/ Murray	director, officer: CEO and President	22643 WOODRIDGE CT, CUPERTINO CA 95014
Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Hugh M Cole	officer: Chief Business Officer	C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Elizabeth Trehu	officer: Chief Medical Officer	C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Kimberlee C Drapkin	officer: CFO and Treasurer	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Third Rock Ventures Iii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Jigar Raythatha	director	C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Third Rock Ventures Ii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
John Duncan Higgons	director	C/O AGIOS PHARMACEUTICALS, INC., 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Luisa Salter-cid	director	C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404